ClinicalTrials.gg
RecruitingNCT07463573Updated Apr 24, 2026

QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

A Phase 3 interventional study of QLC5508 and Investigator's Choice of Chemotherapy (docetaxel, paclitaxel, or Irinotecan Hydrochloride) in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Qilu Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
466
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 401 studies in Esophageal Squamous Cell Carcinoma with a site in China — 174 open to participants now, 213 under way, 32 of them phase 3. Esophageal Squamous Cell Carcinoma · China.

Planned enrollment
34th of 351
466 · median 70
Started
2026
with 47 others
Phase 3
52 of 401
20 open now
Primary completion
2028-06
later than 178 of 212 live
Registered
356th of 401
by date

Among the 401 studies in Esophageal Squamous Cell Carcinoma with a site in China, this one is the 34th largest by planned enrollment of the 351 interventional ones that give a count, is one of 48 that started in 2026, is one of 52 in phase 3, reaches primary completion later than 178 of the 212 other live ones, and was the 356th registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 267 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

174 of the 401 studies in Esophageal Squamous Cell Carcinoma with a site in China are open now. Recruiting first, the newest first:

168 more — sign in →

All 174 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 401 studies in Esophageal Squamous Cell Carcinoma with a site in China, or all of them as a file.
02

Study summary

This study is designed to assess the efficacy and safety of QLC5508 in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following treatment with a platinum-based systemic therapy and an immune checkpoint inhibitor (ICI) compared with investigator's choice of chemotherapy (ICC).

03

Conditions studied

  • Esophageal Squamous Cell Carcinoma (ESCC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily consent to participate in this study and sign the form.
  • Males and females aged ≥18 years old;
  • Performance Status (ECOG PS) score of 0 or 1 within 7 days before the first dose;
  • Estimated survival time of more than 3 months.
  • A serum pregnancy test must be performed within 7 days prior to randomization for premenopausal women of , and the result must be negative and must not be lactating;
  • All enrolled patients and the partners should take adequate barrier during the entire treatment cycle and for 6 months after the end of treatment.
  • Capable of understanding trial requirements, willing and able to comply with trial and follow-up procedures.
  • Toxicity of previous antineoplastic therapy has returned to ≤ grade 1 defined by National Cancer Institute- (NCI-CTCAE) version 6.0 (v6.0);
  • Has or cytologically documented unresectable locally advanced or esophageal squamous cell carcinoma (ESCC) according to American Joint Committee on Cancer 8th edition staging system on ESCC.

    • Has at least 1 according to (RECIST) version 1.1 (v1.1) as assessed by the investigator.
  • Sufficient bone marrow and organ function.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of other primary within 5 years prior to signing the form.
  • Having or cytologically confirmed adenosquamous carcinoma subtype.
  • (unless asymptomatic and no progression confirmed by imaging ≥4 weeks prior to randomization);
  • Presence of or brainstem ;
  • Spinal cord compression (identified via imaging, regardless of symptoms);
  • Previous or ongoing treatment with topoisomerase I inhibitors
  • Having previously received B7-H3-targeted therapy.
  • Being ineligible to any chemotherapies in the control arm due to prior progression or intolerance.
  • Insufficient washout of prior anticancer therapies prior to randomization.
  • Having underwent major organ surgery (excluding ) or significant trauma within 4 weeks prior to randomization;
  • Requiring elective surgery during the study.
  • Having received or live attenuated vaccine within 4 weeks before study randomization.
  • Having received treatment with systemic (prednisone at >10 mg/day, or similar drugs at equivalent dose) or other agents within 14 days prior to randomization;
  • Moderate to severe pulmonary disease significantly impairing lung function, including idiopathic pulmonary fibrosis, /connective tissue disorders with lung involvement, or prior pneumonectomy.
  • Having a history of interstitial lung disease (ILD)/ non-infectious pneumonitis that required corticosteroids, current ILD/ non-infectious pneumonitis, or suspected ILD/ non-infectious pneumonitis that cannot be ruled out by imaging at screening;
  • Active tuberculosis;
  • Autoimmune diseases not in clinical remission, other acquired or congenital immunodeficiency diseases,
  • A history of allogeneic stem cell, bone marrow, or organ transplantation.
  • Serious infections (e.g., bacteremia, or severe pneumonia) within 4 weeks prior to randomization;
  • active infection requiring systemic antibiotic therapy within 1 weeks prior to randomization;
  • Has positive results in virus serology tests ( virus infection participants receiving antiviral treatment other than interferon are allowed to be enrolled);
  • Uncontrolled or significant cardiovascular disease.
  • Clinically uncontrolled third-space effusion.
  • Known to product components, analogues, or control drugs (e.g., docetaxel, paclitaxel, irinotecan hydrochloride).
  • Drug abuse;
  • Any other medical conditions that may interfere with study participation or the results of the clinical study as per the discretion of investigator;
  • Has alcohol or drug dependence.
  • Poor compliance as per investigator discretion;
  • Has a history of other serious systemic diseases.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
466 participants (estimated)

Study arms

  • Experimental
    QLC5508 group

    Drug: QLC5508

  • Active comparator
    Control group

    Drug: Investigator's Choice of Chemotherapy (docetaxel, paclitaxel, or Irinotecan Hydrochloride)

Interventions

  • QLC5508 Injection

  • DrugInvestigator's Choice of Chemotherapy (docetaxel, paclitaxel, or Irinotecan Hydrochloride)

    Investigator's Choice of Chemotherapy (ICC) (docetaxel, paclitaxel, or Irinotecan Hydrochloride)

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Time frame: From baseline to approximately Month 40

Secondary outcomes

  1. Progression-free survival (PFS)

    Time frame: From baseline to approximately Month 40

  2. Objective Response Rate (ORR)

    Time frame: From baseline to approximately Month 40

  3. Duration of Response (DOR)

    Time frame: From baseline to approximately Month 40

  4. Disease Control Rate (DCR)

    Time frame: From baseline to approximately Month 40

  5. Incidence of treatment-emergent adverse events

    Time frame: From the time of the first dose of study drug to 28 days after the last dose of study drug is administered.

  6. Severity of treatment-emergent adverse events

    Time frame: From the time of the first dose of study drug to 28 days after the last dose of study drug is administered.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jun 2028, 25 months after the start.

Of 44 phase 3 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 76. This study's planned 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2026
First posted
Mar 11, 2026
StartActual
Apr 20, 2026
Primary completionEst.
Jun 5, 2028
CompletionEst.
Jul 5, 2029
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07463573
Responsible party
Sponsor
First posted
Mar 11, 2026
Start date
Apr 20, 2026
Primary completion
Jun 5, 2028 (estimated)
Completion
Jul 5, 2029 (estimated)
Last update
Apr 24, 2026

Study contacts

Lin Shen, B.M.
Contact
doctorshenlin@sina.com
+86010-88196561

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QLC5508

Start the discussion